Keto Diet IBS Research and Clinical Trial Evidence
Medically reviewed by Dr. Michael Teplitsky, MD Last reviewed 2026-10-16
A small 2009 study, the 2024 CARIBS trial, and the gap where a ketogenic test would sit
Research on ketogenic diets in IBS is thin. A small uncontrolled 2009 study of a 20-gram carbohydrate limit in IBS-D reported relief, and the CARIBS trial compared a fibre-optimised low-carbohydrate diet with low-FODMAP advice and medical treatment. None of the sources reviewed tested a ketogenic diet in a randomized trial.
Evidence evaluating whether a ketogenic diet improves IBS symptoms remains limited to preliminary and indirect clinical trials. A 2009 uncontrolled study of a 20-gram-per-day very low-carbohydrate diet (VLCD) in diarrhea-predominant irritable bowel syndrome (IBS-D) reported symptom relief, while the 2024 CARIBS trial found that 71 percent of participants on a fibre-optimised low-carbohydrate diet had a reduction of 50 or more points in IBS-SSS over 4 weeks. However, the CARIBS abstract does not describe its diet as ketogenic.
The CARIBS study evaluated 4 weeks of intervention against two active comparisons for irritable bowel syndrome (IBS). A low-FODMAP diet paired with traditional advice achieved a 76 percent response rate. Optimized medical treatment produced a 58 percent response rate.
Want a clinician to work up your metabolic numbers?
Opt Health runs fasting insulin, A1C, a full lipid panel and 50+ other markers, then builds a treatment plan — GLP-1s included where they're appropriate — with a physician who reviews the data with you directly.
See Opt Health's metabolic program →These clinical findings show that evidence for ketogenic protocols in IBS remains sparse. Treatment decisions belong with a licensed clinician.
The 2009 Very Low-Carbohydrate Diet Study
A 2009 prospective study published in Clinical Gastroenterology and Hepatology evaluated whether carbohydrate restriction alters digestive symptoms in IBS-D. The study, indexed as Very low-carbohydrate diet in IBS-D (2009), enrolled 17 participants with moderate to severe symptoms. Participants consumed a standard diet for 2 weeks, followed by 4 weeks on a VLCD providing 20 grams of carbohydrates per day.
The study protocol had no randomized control group. Thirteen of the 17 enrolled participants completed the 4-week dietary intervention. Researchers defined a responder as someone reporting adequate relief of gastrointestinal symptoms for two or more weeks during the VLCD phase.
All 13 completers met the responder definition. Ten participants (77 percent) reported adequate relief across all 4 weeks on the restricted diet. Daily stool frequency dropped from 2.6 ± 0.8 to 1.4 ± 0.6 per day (P < .001), while Bristol Stool Scores improved from 5.3 ± 0.7 to 3.8 ± 1.2 (P < .001).
Pain scores and quality-of-life measures improved significantly alongside bowel frequency changes. The study authors recorded that these symptomatic benefits were independent of weight loss.
The CARIBS Randomized Controlled Trial
The 2024 CARIBS trial examined a low-carbohydrate diet alongside two conventional treatments in adults with irritable bowel syndrome. Conducted as a single-centre, single-blind randomized controlled trial at Sahlgrenska University Hospital in Gothenburg, Sweden, the study enrolled adults with moderate-to-severe IBS under Rome IV criteria. Eligible participants had baseline Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) scores of 175 or higher, as published in the CARIBS randomised controlled trial (2024).Investigators randomly assigned 304 adults in a 1:1:1 ratio. One group consumed a low-FODMAP diet combined with traditional dietary advice recommended by the National Institute for Health and Care Excellence (NICE), labelled as LFTD. A second arm received a fibre-optimised diet low in total carbohydrates and high in protein and fat, while the third received optimized medical treatment based on predominant symptoms.
The clinical intervention lasted 4 weeks. Diet participants were masked to diet names, while the pharmacological treatment was open-label. Of 294 analysed participants, 82 percent were women, with a mean cohort age of 38 years and a standard deviation (SD) of 13.
The primary endpoint was the proportion of participants achieving an IBS-SSS reduction of 50 or more points from baseline. In the analysed groups, 73 of 96 participants (76 percent) in the LFTD group met the endpoint, compared with 69 of 97 (71 percent) in the low-carbohydrate group. The medical-treatment arm recorded 59 responders out of 101 participants (58 percent), reflecting a statistically significant difference across groups (p=0.023).
| Treatment Arm | Analysed Participants | Responders (IBS-SSS Drop ≥50) | Response Rate | 4-Week Completion Rate |
|---|---|---|---|---|
| Low-FODMAP plus NICE advice (LFTD) | 96 | 73 | 76% | 95% |
| Fibre-optimised low-carbohydrate | 97 | 69 | 71% | 95% |
| Optimised medical treatment | 101 | 59 | 58% | 90% |
Completion of the 4 weeks was 95 percent in each diet group and 90 percent in the medical-treatment group. No serious adverse events occurred. Five of 91 individuals (5 percent) in the medical-treatment group discontinued therapy due to side-effects.
The authors concluded that both diets and medical therapy reduced IBS severity, with larger improvements observed in the dietary arms. They noted that dietary interventions might be considered an initial treatment for IBS; the diets tested were low-FODMAP and fibre-optimised low-carbohydrate.
Low-Carbohydrate Versus Ketogenic
The CARIBS abstract does not describe its low-carbohydrate diet as ketogenic. The abstract gives no daily carbohydrate gram target.
The 2009 study evaluated a very low-carbohydrate diet providing 20 grams of carbohydrates per day. The CARIBS diet was described as fibre-optimised, low in total carbohydrates and high in protein and fat.
What the Evidence Does Not Show
No randomized trial of a ketogenic diet in IBS appears in the sources reviewed here, and CARIBS was 4 weeks of intervention at a single centre. The 2009 study lacked a control group, followed only 13 completers, and evaluated participants with IBS-D exclusively. Claims that a keto diet cures or treats IBS remain unsupported.
Clinical Evaluation of Dietary Interventions
Questions about IBS symptoms or dietary changes belong with a licensed clinician.
Frequently Asked Questions
Can a keto diet improve IBS?
Available clinical research remains limited. A small uncontrolled 2009 study found that a 20-gram-per-day very low-carbohydrate diet improved stool frequency and pain scores in the 13 participants who completed it (17 enrolled) with diarrhea-predominant irritable bowel syndrome (IBS-D). However, that trial lacked a control group. The larger 2024 CARIBS trial evaluated a low-carbohydrate diet that its abstract does not describe as ketogenic, meaning clinical evidence for ketogenic protocols in IBS is currently absent.
Is there a randomized trial of keto for IBS?
No randomized controlled trial evaluating a ketogenic diet specifically for irritable bowel syndrome appears in the sources reviewed here. The 2024 CARIBS study was a randomized controlled trial testing a fibre-optimised low-carbohydrate diet, but its protocol was not designated as ketogenic and did not specify a carbohydrate gram target. The 2009 study investigating a 20-gram carbohydrate limit was an uncontrolled study.
How did a low-carbohydrate diet compare with low-FODMAP in CARIBS?
In the CARIBS trial, 71 percent (69 of 97) of participants in the low-carbohydrate group achieved a reduction of 50 or more points on the Irritable Bowel Syndrome Symptom Severity Scale. In the group receiving a low-FODMAP diet plus traditional advice, 76 percent (73 of 96) reached that endpoint. Both dietary groups had higher response rates than optimized medical treatment, which had 58 percent.
Does a very low-carbohydrate diet help IBS-D?
Data from an uncontrolled 2009 study showed preliminary symptomatic relief in diarrhea-predominant irritable bowel syndrome. All 13 participants who completed 4 weeks of a 20-gram daily carbohydrate limit experienced adequate symptom relief for two or more weeks. Stool frequency decreased significantly from 2.6 to 1.4 stools per day, and stool consistency improved on the Bristol Stool Score.
Related Reading
Related guides:
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want your metabolic health handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results